



A systematic review of interventions to improve adherence to endocrine therapy

Sue P. Heiney¹ · Pearman D. Parker² · Tisha M. Felder³ · Swann Arp Adams³ · Omonefe O. Omofuma⁴ · Jennifer M Hulett²

Received: 8 June 2018 / Accepted: 15 October 2018 / Published online: 1 November 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

Purpose Adherence to endocrine therapy for hormone positive breast cancer is a significant problem, especially in minority populations. Further, endocrine therapy reduces recurrence and thus mortality. However, little data are available on interventions to improve adherence. The authors conducted a systematic review to examine the impact of interventions, strategies, or approaches aimed to improve endocrine therapy adherence among women with breast cancer. A secondary aim was to determine if interventions had any cultural modifications.

Methods Two of the authors examined articles published between 2006 and 2017 from a wide variety of databases using Covidence systematic review platform.

Results In total, 16 eligible studies met criteria for review including 4 randomized controlled trials, 4 retrospective studies, and 8 with various observational designs. Eligible studies used a broad range of definitions for adherence and measured adherence by self-report, medical records, claims data, and combinations of these. All used 80% medication possession ratio as a standard for adherence. Patient information/education was the most frequent intervention strategy but did not demonstrate a significant effect except in one study. Significant results were noted when education was combined with communication strategies.

Conclusions Researchers need a standard definition for adherence and a reliable measure that is feasible to use in a variety of studies. While education may be a necessary component of an intervention, when used alone, it is not a sufficient approach to change behavior.

Keywords Breast cancer · Endocrine therapy · Adherence · Systematic review · Interventions

Introduction

Approximately, two-thirds of diagnosed breast cancers (BrCas) in the United States are hormone-receptor positive. Endocrine therapy (ET), the recommended adjunct treatment for hormone-receptor positive BrCa, can reduce recurrence

by 40% and lower the risk of dying by one-third [1]. Despite these survival benefits, adherence to ET is a major problem [2–13]; 50–75% of all women prescribed ET prematurely discontinue or do not maintain adherence after 5 years [6, 9, 14–17]. Even lower rates of ET adherence occur among sub-groups of financially disadvantaged women [18]; and, in some cases, are significantly lower among women who are both African American and are of low-income status [19, 20]. With more recent findings indicating the need to continue ET for 10 years, adherence may be even more problematic [14, 21]. Therefore, identifying effective interventions to improve maintenance of ET in women with BrCa is vital [17, 22, 23].

Previous studies have extensively documented socio-demographics, e.g., race, age, disease, and treatment-related factors are associated with ET adherence, and provided limited evidence about modifiable factors, e.g., psychosocial,

✉ Sue P. Heiney
heineys@mailbox.sc.edu

¹ College of Nursing, School of Medicine, University of South Carolina, 1601 Greene St, Columbia 29208, SC, USA

² College of Nursing, University of South Carolina, Columbia, USA

³ College of Nursing, Arnold School of Public Health, University of South Carolina, Columbia, USA

⁴ Arnold School of Public Health, University of South Carolina, Columbia, USA

behavioral, which can be targeted with interventions [13, 24–26]. A systematic review by Hurtado-de-Mendoza et al. [50] confirmed that few behavioral intervention studies were conducted on improving adherence to ET therapy. Therefore, the purposes of this systematic review were to explore studies that examined the impact of interventions or strategies to improve ET adherence among women with BrCa, and identify studies offering insights for future researchers designing interventions to improve ET adherence. Given the known health disparities of BrCa survivors that may contribute to lack of ET adherence [18, 27, 28], we additionally sought to examine whether any studies discussed adaptations or considerations aimed to target the unique needs of disparate populations.

Methods

Inclusion and exclusion criteria

Studies included in this review met the following criteria: original research in peer-reviewed journals, full-text available online, clearly stated descriptions of samples and methodology, human subjects, adults, and articles available in English. We focused on papers that examined strategies and approaches for improving adherence to ET among women with BrCa. We defined ET as tamoxifen and/or aromatase inhibitors, the two major classes of drugs used for hormone positive BrCa. We included studies with a broad range of designs to capture data that examined a direct relationship between adherence and any strategy that could be replicated in an intervention. For example, if a study reported modifiable factors, e.g., self-efficacy, patient-provider communication in association with adherence as an outcome, we included the study. We excluded any descriptive manuscripts which did not document strategies to improve adherence.

Search strategy

Articles from 2006 to 2017 were retrieved from the following databases: PubMed, CINAHL, PsychInfo, Web of Science, and Cochrane Library. The MeSH terms and keywords included *patient compliance* [MeSH Terms] OR *patient compliance* [All Fields] OR *medication adherence* [MeSH Terms] OR “*medication adherence*”[All Fields] OR “*treatment adherence*”[All Fields]) AND (“*breast neoplasms*”[MeSH Terms] OR “*breast neoplasms*”[All Fields] OR “*breast cancer*”[All Fields]) AND “*antineoplastic agents, hormonal*”[All Fields] OR “*antineoplastic agents, hormonal*”[MeSH Terms] OR “*aromatase inhibitors*”[All Fields] OR “*aromatase inhibitors*”[MeSH Terms] OR *aromatase inhibitors*[Text Word] OR “*endocrine therapy*”[All Fields].

Study screening

We imported and managed all study citations identified from our search strategy with the Covidence systematic review platform [29]. Two reviewers (P.H., S.H.) independently screened titles and abstracts for study eligibility, and identified studies for full-text review. Reviewers independently read the full text and selected studies for inclusion. Following this review, the two reviewers met to reach consensus on the final selection of studies to be included.

Data abstraction

Data selected for extraction and included in Table 1 are author/date, sample size, inclusion criteria, drug type, adherence measure, design, intervention detail, results, and cultural aspects. We based our risk-of-bias assessment on work by Chad-Friedman and colleagues who used a checklist adapted from STROBE recommendations [30] to review studies in their systematic review [31].

Results

Study selection

Figure 1 provides a flowchart of the identification, screening, and article selection process, which initially resulted in 1254 original articles about strategies to improve ET adherence. After removing duplicates ($n = 304$), we screened 950 titles and abstracts for study eligibility. From this process, 38 articles were selected for the full-text review. A total of 16 articles were included in the final review; one of the 16 papers reported on the same study at different time intervals, i.e., 1 year and final report [32, 33].

Overview of study characteristics

We observed a variety of study designs, adherence definitions, and measurement approaches that are presented in Table 1. Eight studies reported inclusion of either tamoxifen or aromatase inhibitors, seven reported inclusion of only aromatase inhibitors, and one study examined tamoxifen only.

Risk of bias

The risk of bias varied considerably due to the diverse nature of the study designs, e.g., RCT, cross sectional, and quasi-experimental. All studies reported inclusion criteria; sampling methods were appropriate to the design (randomized or convenience). As expected, sample size was quite large in

Table 1 Data extraction table for intervention approaches to adherence

Source	Sample size	Drug type	Measurement	Design	Retrospective descriptive	Type of manipulation	Results	Cultural aspects
Albert 2011 [47]	207	Tam and AI	Self report of medication adherence from questionnaire	Retrospective		Patient's interaction with the breast care nurse	Nurse navigator contact and knowledge of hormone receptor status significantly correlated ($p < 0.001$)	Germany
Arriola 2014 [38]	200	Tam and AI	MARS (4 items), Drug Attitude Inventory (6 items) higher score greater adherence	Cross sectional		Physician communication frequency	Frequency of physician communication was significantly associated with medication adherence ($p < 0.05$)	US White, 54.5%
Castaldi 2017 [46]	117	Tam and AI	Days to ET start using National Quality Forum 2	Non-randomized historical usual care versus navigated care		SC versus Multi-disciplinary Patient Navigation program	SC (68.6%) versus navigation (100%) $p < 0.0001$	US AA 45% Hispanic 28.5% Asian 8% White 8.5%
Hadji 2013 [40]	Treatment (2442)/SC (2402)	AI	Self-report questionnaire and percentage of patients adherent at 12 month based on prescription given	RCT		SC versus Educational materials	SC (52.3%) vs. Educational materials (50.9%) $p = 0.37$	Germany
Heisig 2015 [43]	137	Tam and AI	Self-assessment question of number of tablets taken in the last 12 weeks	Prospective single cohort		SC versus enhanced education with printed materials and verbal instruction	Adherence significant for satisfaction with ET information ($p = 0.17$, OR 1.55 $p = 0.03$, $n = 133$) and associated problems ($p = 0.22$, OR 1.77, $p = 0.006$)	Germany
Jacob 2015 [34]	1874 (DMP); 3041 (SC)	Tam and AI	90 days without medication refill over 3 year period	Retrospective		SC versus disease management program	SC (39.6%) versus Disease Management (32.7%) adjusted HR 0.91; 95% CI 0.85–0.98	Germany
Kahn 2007 [42]	881	Tam	Self-report survey; medical record	Prospective cohort		Patient-centered care	Three factors, amount of support, role in decision making and pre-treatment information on side effects was significantly associated with tamoxifen adherence	US Hispanic & other 5% Non-Hispanic white 85% Non-Hispanic other 4% Black 7%

Table 1 (continued)

Source	Sample size	Drug type	Measurement	Design	Type of manipulation	Results	Cultural aspects
Kostev 2013 [35]	3620	Tam	90 days without medication refill	Retrospective	Conversion versus no conversion to a rebate	44.2% of women who used a rebate process and 33.8% of patients who continued with same process discontinued their treatment ($p < 0.01$) after one year	Germany
Lin 2017 [44]	100	Tam and AI	MARS (4 item)	Cross sectional	Patient provider communication	Physician communication not associated ($p > 0.05$) with adherence	USA
Liu 2013 [37]	303	Tam and AI	Self report 3 years post diagnosis	Observational	Patient-provider communication	Patient centered communication by oncologist significantly predicted adherence at 3 years post diagnosis (AOR 1.22, $p = 0.006$)	US Latina 49% White 34%
Markopoulos 2015 [32]	1379 per group	AI	Self report number of pills taken; number of Rx written	RCT	Educational materials versus SC	SC (82%) versus Education (82%) no significant difference 1 year and similar at 2 years	Lead country Belgium International study Across 18 countries
Neugut 2011 [36]	Pre-medicare 8110; Medicare 14,050	AI	Minimum 45-day supply gap with no AI on hand and no refills	Retrospective cohort	Co-payment amount	90-day co-payment (\$90 or more) in younger women compared to a co-payment of \$30 (OR 0.82, 95% CI 0.72–0.94). Older women had similar negative findings regarding the co-payment amounts of \$30 or more compared with co-payment amounts of less than \$30 OR 0.72, 95% CI 0.65–0.80) respectively	USA White 89/5% Black 4.7% Hispanic 3% Asian 1.8%

Table 1 (continued)

Source	Sample size	Drug type	Measurement	Design	Type of manipulation	Results	Cultural aspects
Neuner 2015 [36]	16,462	AI	Number of days prescription received for 3 months	Quasi-experimental pre-post	Amount of Copay	Generic anastrozole introduction increased probability of adherence by 5.4% and with letrozole/exemestane 11% higher probability	USA
Neven 2014 [33]	1379 per group	AI	How many tablets taken during the past year (nearly all)	RCT	SC versus Educational materials	SC (81%) versus Educational Materials $p=0.4524$	Austria Switzerland Sweden/Finland
Yu 2012 [39]	Treatment (252) /SC (264)	AI	Proportion of days covered by prescription refills over the 364 days following the initiation of AI	Prospective, controlled, observational	SC versus standard treatment plus patient support program group	SC (95.9%) versus Educational materials and reminder calls (95.8%) $p=0.95$	China
Ziller 2013 [41]	181	AI	Self reported adherence and an MPR of 80% or more	RCT, 3 arms	SC versus reminder letters, information booklets versus reminder letter, telephone calls	SC (48.0%) versus letter group (64.7%) versus phone call group (62.7%) $p=0.75$	Germany

SC standard care, Tam tamoxifen, AI Aromatase inhibitors, RCT randomized controlled trial, CI confidence interval, OR odds ratio, ET endocrine therapy, AOR adjusted odds ratio




Fig. 1 PRISMA (Preferred reporting items for systematic reviews and meta-analyses) flow

the database studies (range from 4915 to 22,160). Large samples were also reported in several of the RCT studies (about 2700 participants). Human subjects' review according to US or international standards was reported in 10 papers ($n=16$). Four papers used publicly available de-identified data from a claims' database and may have been exempt from review [34–37]. Two papers did not report on human subjects' protection [33, 38]. However, one of the papers was from the same study [33] in which the final paper reported the ethics review [32]. The population was adequately described in the studies. Most of the studies addressed bias usually through a discussion of limitations. Only two studies omitted any discussion of bias [35, 39].

Study designs

We used the authors' description of their study design as published in their paper. Two designs (RCT and retrospective) were most commonly used with four papers each [32, 33, 40, 41]. Other designs reported included three prospective, [39, 42, 43] two cross sectional [38, 44], and one each of observational [37], quasi-experimental [45], and historical usual care versus an intervention [46]. Table 2 shows studies by design that was significantly associated with adherence and provides information on intervention strategies.

Definitions and measurement of adherence

Authors differed as to terminology about adherence and used adherence or compliance/compliant [32, 33, 36, 40, 41, 45], non-adherence [43, 44], persistence [32, 39], non-persistence

[35, 36] and discontinuation [32, 34, 35, 39]. Also, authors may have measured two different constructs within one study, commonly whether the patient was taking the drug, e.g., adherence and the time period of taking the drug, e.g., persistence. Compliance and adherence had similar definitions whether by self-report or objective measures such as prescription refill. Participants were considered adherent if they had received or taken 80% of the drug dispensed and in some cases for analyses, this was dichotomized to 80% as being adherent and below 80% as not adherent [36, 43]. Discontinuation was defined as lack of continuation of hormone therapy within a specified study time period, e.g., 90 days [34, 35]. The definition of non-persistence was similar; but the author used a time period within which the drug had not been refilled [36]. Persistence was defined as the ongoing use or continuation of hormonal therapy within the specified study time period from initiation to discontinuation; studies lasted from 1 to 4 years [42, 46].

Data were obtained from self-report exclusively ($n=3$) [37, 44, 47], self-report and other corroborating data ($n=8$) [32, 33, 38–40, 42, 43, 47, 48], only medical records ($n=1$) [46] de-identified data sets from electronic medical records ($n=2$) [34, 35] and claims data ($n=2$) [36, 45]. Regardless of the source of data, half of the authors used 80% as the standard for adherence as determined by a calculated medication possession ratio or a self-report that provided a similar score [32, 33, 36, 39, 40, 43, 45].

Impact of interventions to improve ET adherence

The most frequent intervention strategy reported was patient information/education ($n=5$). Other strategies included communication between the patient and health care team members ($n=5$), education and communication ($n=2$), patient navigation ($n=2$), and financial changes ($n=3$). All educational interventions used similar components such as educational materials on various aspects of ET, which were mailed to patients at intervals; although, none of these reported significant results [32, 33, 39–41]. However, one of these studies did show significant results in Sweden and Finland [33]. Two studies combined education and communication and both of these studies had significant results [34, 43]. Similarly, patient navigation, facilitating the patient's process from diagnosis through treatment showed significant ET adherence [46, 47]. Details about the interventions are provided in Table 1.

The majority of the studies ($n=9$) were conducted outside the United States: Germany ($n=6$) [34, 35, 40, 41, 43, 47] China ($n=1$) [39] and several European/Scandinavian countries in multi-site cooperative studies ($n=2$) [32, 33]. Of the seven studies conducted in the US, the majority of the participants were white ($n=5$) with white participants ranging from 54% to 89.5% [36, 38, 42, 44, 45]. One study had

Table 2 Intervention type and study design with results

Author	Intervention type	Type of manipulation	Measure	Design	Results
Arriola 2014 [38]	Communication	Physician communication frequency	SR	Cross sectional	S–Frequency of physician communication was significantly associated with medication adherence ($p < 0.05$)
Lin 2017 [44]	Communication	Patient provider communication	SR	Cross sectional	NS–Endocrine therapy adherence was not associated ($p > 0.05$) with physician communications although the majority of the patients reported positive physician communications
Castaldi 2017 [46]	Patient navigation	Multi-disciplinary Patient Navigation program versus SC	Other	Non-randomized historical usual care versus navigated care	S–Navigation Program clearly demonstrated improved compliance with follow-up and adjuvant therapy in a predominantly minority population. Compliance for NQF measure 1 in NC is 100% versus 57.1% in UC ($p = 0.005$). Compliance for NQF measure 2 in NC is 100% versus 68.6% in UC ($p < 0.0001$)
Liu 2013 [37]	Communication	Patient-provider communication	SR	Observational	S–The use of endocrine therapy 3 years after diagnosis was positively predicted (AOR = 1.22, $p = 0.006$) by women's report that their oncologist used patient-centered communication which was assessed at 18 months after diagnosis
Kahn 2007 [42]	Communication	Patient-centered care	SR and other	Prospective cohort	S–Tamoxifen use was significantly higher ($p = 0.0051$) in those women who reported receiving the right amount of support (79%). Adherence was lower when women (81%) were less satisfied with decision making role ($p = 0.0001$) and when decision made alone (56%) ($p = 0.0003$). Adherence lower ($p < 0.0001$) in women who were not informed about side effects prior to experiencing them (62% vs. 85%)
Heisig 2015 [43]	Education	SC versus enhanced education (printed materials and verbal instruction)	Other	Prospective single cohort	S–Adherence significant for satisfaction with ET information ($p = 0.17$, OR 1.55 $p = 0.03$, $n = 133$) and associated problems ($p = 0.22$, OR 1.77, $p = 0.006$)
Yu 2012 [39]	Support group	SC versus standard treatment plus patient support program group	Other	Prospective, controlled, observational	NS–Patients in the standard care group stopped use of endocrine therapy at 213.2 days and in the intervention group at 227.8 days; there was no significant difference in the length of time for discontinuation ($p = 0.96$)

Table 2 (continued)

Author	Intervention type	Type of manipulation	Measure	Design	Results
Neuner 2015 [45]	Financial	Amount Copy	Other	Quasi-experimental pre-post	S-Generic anastrozole introduction increased probability of adherence by 5.4% and with letrozole/exemestane 11% higher probability
Hadji 2013 [40]	Education	SC versus educational materials	SR and other	RCT	NS—no difference in rates between the standard and EM arms (50.9% and 52.3%, respectively, $p = 0.37$)
Markopoulos 2015 [32]	Education	Educational materials versus SC	SR and other	RCT	NS—end of study results (CARIATIDE) Educational materials did not significantly impact adherence in any country
Neven 2014 [33]	Education	Educational materials versus standard	SR	RCT	S by country—Year 1 Results (CARIATIDE): Educational materials only improved overall adherence with AI in Sweden/Finland; ($p = 0.0246$)
Ziller 2013 [41]	Education	Reminder letters, information booklets versus reminder letter, telephone calls versus SC	SR and Other	RCT, 3 arms, partially-blinded parallel group	NS—No differences were found in adherence at 1 year post treatment initiation among control group (48.0%) letter group 64.7% or phone call group 62.7%. Post hoc analysis of combined intervention groups versus control was significantly different ($p = 0.039$)
Jacob 2015 [34]	Education	Disease management program versus SC	Other	Retrospective	S—DMP patients versus SC showed significant difference ($p = 0.001$) in discontinuing endocrine therapy within 3 years (32.7% versus 39.6%). Risk for discontinuing endocrine therapy was lower in DMP patients than standard care (adjusted HR 0.91, 95% CI 0.85–0.98)
Kostev 2013 [35]	Financial	Conversion versus no rebate conversion	Other	Retrospective	NS—Switching patients to a rebate pharmaceutical process had a significantly negative effect on adherence at 1 year and 3 years. Discontinuation of treatment was significantly higher at 3 years (HR 1.27, CI 1.05–1.53, $p = 0.014$) 44.2% of women who used a rebate process and 33.8% of patients who continued with same process discontinued their treatment ($p < 0.01$) after 1 year

Table 2 (continued)

Author	Intervention type	Type of manipulation	Measure	Design	Results
Neugut 2011 [36]	Education	Co-payment amount	Other	Retrospective cohort	S–In younger women, the amount of a 90-day co-payment (\$90 or more) was significantly associated with non-adherence when compared to a co-payment of \$30 (OR 0.82; 95% CI 0.72–0.94). Older women had similar negative findings regarding the co-payment amounts of \$30 or more compared with co-payment amounts of less than \$30 OR 0.72, 95% CI 0.65–0.80) respectively
Albert 2011 [47]	Patient navigation	Patient's interaction with the breast care nurse	SR	Retrospective descriptive	S–Adherence was significantly correlated ($p < 0.001$) with nurse navigator contact (79 contact versus 56% no contact) and knowledge of hormone receptor status

SC standard care, Tam tamoxifen, AI Aromatase inhibitors, RCT randomized controlled trial, CI confidence interval, OR odds ratio, ET endocrine therapy, AOR adjusted odds ratio, S significant, NS not significant

relatively high African American participation (45%) [46]. The majority of participants in one study, based in California, were Latina (54%) [37]. An examination of these studies that included African American and Latina populations did not find any evidence that any cultural adaptations were made. An exception [46] used navigated care for a racially diverse cohort of participants. The description of navigation suggested that cultural adjustments were made, such as using bilingual (Spanish and English) navigators, and additional support was provided by American Cancer Society volunteer navigators [46].

Discussion

This systematic review extended previous work by identifying and describing a broader range of studies on approaches to improve adherence to ET in women with breast cancer. Of the sixteen studies included in this review, only four were RCTs. While the RCT design yields the highest quality of scientific evidence, we found that the researchers who used this design proposed “educational only” interventions that did not lead to statistically significant improvements in ET adherence; except one study reported significant differences in adherence by country. This finding supports the notion that while education may be a necessary part of an intervention, it is not sufficient for behavior change [49]. In fact, the two interventions that combined education and communication reported significant results.

Our findings of inconsistent definitions and measurement of treatment adherence were similar to Hurtado-de-Medoza and colleagues [50]. This lack of consistency limited interpretation of findings. Further, the source of the data in four studies was self-reported which decreased credibility of the findings [51]. Approaches to increase the scientific rigor of future studies could include longitudinal designs [52], electronic monitoring [53], valid and reliable self-report measures [54] and biomarkers such as measurement of tamoxifen in a dried blood spot [55].

Health care provider interaction, positive communication, and education are important to patient understanding and adherence [37, 38, 43, 46, 47]. A standardized program of patient navigation [46] or disease management [34] had significant impact on adherence. In the disease management program patients received tailored information and individual consultation as well as assistance with transition between inpatient and outpatient care [34]. In the patient navigation program, patients received information in English or Spanish and were supported through care transitions [46]. In both these cases, the approach was patient centered and adaptable to specific needs of the patient through the continuum of care. In contrast, six studies used well developed educational materials that were provided over time via mail and phone

[32, 33, 39–41, 43]. While the exact education about the hormonal therapy was not detailed in the papers, in general the educational materials covered benefits, side effects, and other pertinent details about cancer treatment. However, this information was not individualized to the patient. Specific content about the BrCA diagnosis may be needed to help patients understand the critical reason for taking hormonal therapy, such as hormone receptor status [47]. Therefore, researchers and providers should determine what content and delivery method works best.

A theoretical approach was used in only one study to frame and direct the components of the intervention [41]. Use of theory leads to better design of intervention components and outcomes [56–59]. Theories that could be used in adherence interventions include planned behavior [60], and self regulation [61]. Additionally, frameworks, such as the World Health Organization's Multidimensional Adherence model [62], could also be useful for planning and evaluating multi-level intervention approaches to improving long-term adherence to ET.

Another weakness of all studies is that none of reported on treatment fidelity [62] which is a critical component to improve the quality of interventions [63–65]. Treatment fidelity includes an evaluation of the intervention to determine if it was delivered as planned and an assessment of participants' to establish exposure to the intervention. Even interventions that have been pilot tested may not show an effect and this could be due to problems with fidelity [66]. We speculate that treatment fidelity might account for differences found in a multi-site trial where significant changes were demonstrated in the intervention group by country [33].

Conclusions

Based on this review, much work remains in the development and testing of interventions to improve ET adherence and adapt interventions to diverse cultures and ethnicities. In this review, of the US studies, none described any cultural adaptation even though both diverse cultures were represented in the samples. Yet, research shows that cultural adaptation is necessary for interventions to be well accepted and adopted by various cultural groups [67–69]. Further, cultural adaptation strengthens the effects of the intervention [22, 70–72]. For example, our work with STORY (Sisters Tell Others and Revive Yourself) demonstrates the effectiveness of a culturally sensitive intervention that improved mood and social connection. Further, secondary analysis of this work found that although adherence was not an outcome of the original study, we documented that intervention participants significantly increased treatment-specific knowledge [73].

More research is needed in the US where individual health care plans may particularly impact ET adherence.

Future interventions should address potential financial and economic barriers to adherence including access to discount pharmaceutical programs [74].

We observed a need for standardization of terminology, definitions, and measurement in order to compare findings across studies. Although an 80% medication possession ratio (MPR) is considered adherent, it remains unknown whether this reaches a therapeutic drug level. Measures to determine ET adherence should be used as crosschecks against measurement error, e.g., self-report combined with automated electronic monitoring. Well planned RCTs that include effective intervention components such as communication and education should be implemented. Finally, cancer researchers and clinicians should learn from existing literature on successful intervention in other chronic conditions. Notably, AIDS/HIV work shows theories and models that could be applicable to cancer [75–77].

Author contributions SH: Conceptualization and plan for this review, completed the article screening, selection, and data extraction; assisted with data synthesis and contributed to the manuscript preparation. TF: Conceptualization and plan for this review; assisted with data synthesis and contributed to the manuscript preparation. PP: Contributed to the conceptualization and plan for this review, completed the article screening, selection and data extraction; assisted with data synthesis and contributed to the manuscript preparation. OO: Completed the article screening, selection, and data extraction; assisted with data synthesis and contributed to the manuscript preparation. SA: Assisted with data synthesis and contributed to the manuscript. JH: Assisted with review and editing of the manuscript.

Funding Dr. Felder was supported by a Mentored Research Scientist Development Award to promote diversity from the National Cancer Institute of the National Institutes of Health (K01CA193667). Parker was supported by a training Grant from the Susan G. Komen® Foundation (GTDR17500160). Babatunde was supported by grant # 1F99CA22272201 from the National Cancer Institute. Heiney received partial funding for this paper from an ASPIRE grant from the Vice President of Research Office, University of South Carolina.

Compliance with ethical standards

Conflict of interest The authors have no conflicts.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Early Breast Cancer Clinical Trialsists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials *Lancet* 365(9472):1687–1717
2. Fontein DBY, Nortier JWR, Liefers GJ et al (2012) High non-compliance in the use of letrozole after 2.5 years of extended

- adjuvant endocrine therapy. Results from the IDEAL randomized trial. *EJSO* 38(2):110–117
3. Kesmodel SB, Goloubeva OG, Rosenblatt PY et al (2018) Patient-reported adherence to adjuvant aromatase inhibitor therapy using the Morisky Medication Adherence Scale: an evaluation of predictors. *Am J Clin Oncol* 41(5):508–512
 4. Kimmick G, Edmond SN, Bosworth HB et al (2015) Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. *Breast* 24(5):630–636
 5. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. *Br J Cancer* 108(7):1515–1524
 6. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. *J Clin Oncol* 27(21):3445–3451
 7. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. *J Clin Oncol* 26(4):556–562
 8. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. *J Clin Oncol* 21(4):602–606
 9. Wheeler SB, Kohler RE, Reeder-Hayes KE et al (2014) Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. *J Cancer Surviv* 8(4):603–610
 10. Gotay C, Dunn J (2011) Adherence to long-term adjuvant hormonal therapy for breast cancer. *Expert Rev Pharmacoecon Outcomes Res* 11(6):709–715
 11. Wu J, Stafkey-Mailey D, Bennett CL (2012) Long-term adherence to hormone therapy in medicaid-enrolled women with breast cancer. *Health Outcomes Res Med* 3(4):e195–e203
 12. Yung RL, Hassett MJ, Chen K et al (2012) Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. *J Natl Cancer Inst* 104(14):1102–1105
 13. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Br Cancer Res Treat* 134(2):459–478
 14. McCowan C, Shearer J, Donnan PT et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. *Br J Cancer* 99(11):1763–1768
 15. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. *J Clin Oncol* 28(27):4120–4128
 16. Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. *Medicare Medicaid* 1(4):E1–E25
 17. Chlebowski RT, Kim J, Haque R (2014) Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. *Cancer Prev Res* 7(4):378–387
 18. Ursem CJ, Bosworth HB, Shelby RA, Hwang W, Anderson RT, Kimmick GG (2015) Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. *J Womens Health* 24(5):403–408
 19. Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI (2015) Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. *J Clin Oncol* 33(9):1053–1059
 20. Farias AJ, Du XL (2017) Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer. *J Clin Oncol* 35(1):86–95
 21. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. *Breast Cancer Res Treat* 130(2):681–689
 22. Sheppard VB, Wallington SF, Willey SC et al (2013) A peer-led decision support intervention improves decision outcomes in black women with breast cancer. *J Cancer Educ* 28(2):262–269
 23. Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. *Oncologist* 18(9):986–993
 24. Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD (2017) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. *Patient Prefer Adherence* 11:305–322
 25. Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: a systematic review and meta-analysis. *Patient Educ Couns* 98(12):1524–1539
 26. Van Liew J, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. *J Cancer Surviv* 8(3):521–531
 27. McCarthy AM, Armstrong K, Yang J (2015) Increasing disparities in breast cancer mortality from 1979 to 2010 for US black women aged 20 to 49 years. *Am J Public Health* 105(Suppl(3):S446–S448
 28. Reeder-Hayes KE, Meyer AM, Dusetzina SB, Liu H, Wheeler SB (2014) Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. *Breast Cancer Res Treat* 145(3):743–751
 29. Covidence [computer program]. 2017
 30. von Elm E, Altman DG, Egger M et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 61(4):344–349
 31. Chad-Friedman E, Coleman S, Traeger LN et al (2017) Psychological distress associated with cancer screening: a systematic review. *Cancer* 123(20):3882–3894
 32. Markopoulos C, Neven P, Tanner M et al (2015) Does patient education work in breast cancer? Final results from the global CARIATIDE study. *Future Oncol* 11(2):205–217
 33. Neven P, Markopoulos C, Tanner M et al (2014) The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. *Breast* 23(4):393–399
 34. Jacob L, Hadji P, Albert US, Kalder M, Kostev K (2015) Impact of disease management programs on women with breast cancer in Germany. *Breast Cancer Res Treat* 153(2):391–395
 35. Kostev K, May U, Hog D et al (2013) Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany. *Int J Clin Pharmacol Ther* 51(12):969–975
 36. Neugut AI, Subar M, Wilde ET et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. *J Clin Oncol* 29(18):2534–2542
 37. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. *Breast Cancer Res Treat* 137(3):829–836
 38. Arriola KRJ, Mason TA, Bannon KA et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. *Patient Educ Couns* 95(1):98–103

39. Yu KD, Zhou Y, Liu GY et al (2012) A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. *Breast Cancer Res Treat* 134(1):307–313
40. Hadji P, Blettner M, Harbeck N et al (2013) The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. *Ann Oncol* 24(6):1505–1512
41. Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study. *BMC Cancer* 13(1):1–9
42. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. *Med Care* 45(5):431–439
43. Heisig SR, Shedden-Mora MC, von Blanckenburg P et al (2015) Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. *Psychooncology* 24(2):130–137
44. Lin JJ, Chao J, Bickell NA, Wisnivesky JP (2017) Patient-provider communication and hormonal therapy side effects in breast cancer survivors. *Women Health* 57(8):976–989
45. Neuner JM, Kamaraju S, Charlson JA et al (2015) The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. *J Natl Cancer Inst*. <https://doi.org/10.1093/jnci/djv130>
46. Castaldi M, Safadjou S, Elrafei T, McNelis J (2017) A multidisciplinary patient navigation program improves compliance with adjuvant breast cancer therapy in a public hospital. *Am J Med Qual* 32(4):406–413
47. Albert US, Zemlin C, Hadji P et al (2011) The impact of breast care nurses on patients' satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. *Breast Care* 6(3):221–226
48. Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. *Ann Oncol* 20(3):431–436
49. Wing RR (2000) Cross-cutting themes in maintenance of behavior change. *Health Psychol* 19(1S):84–88
50. Hurtado-de-Mendoza A, Cabling ML, Lobo T, Dash C, Sheppard VB (2016) Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review. *Clin Breast Cancer* 16(4):247–255
51. Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L (2013) Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. *Patient Prefer Adherence* 7:675–682
52. Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS Jr (2011) Improving the measurement of self-reported medication nonadherence. *J Clin Epidemiol* 64(3):250–254
53. Sutton S, Kinmonth A-L, Hardeman W et al (2014) Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity. *Ann Behav Med* 48(3):293–299
54. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB (2004) The concordance of self-report with other measures of medication adherence: a summary of the literature. *Med Care* 42(7):649–652
55. Tre-Hardy M, Capron A, Antunes MV, Linden R, Wallemacq P (2016) Fast method for simultaneous quantification of tamoxifen and metabolites in dried blood spots using an entry level LC-MS/MS system. *Clin Biochem* 49(16–17):1295–1298
56. Rothman AJ (2000) Toward a theory-based analysis of behavioral maintenance. *Health Psychol* 19(1, Suppl):64–69
57. Given B, Given C, Sikorskii A (2007) Deconstruction of a nursing intervention to examine the mechanism of action. *Oncol Nurs Forum* 34(1):199
58. Song M-K, Ward SE (2015) Making visible a theory-guided advance care planning intervention. *J Nurs Scholarsh* 47(5):389–396
59. Irwin M (2015) Theoretical foundations of adherence behaviors: synthesis and application in adherence to oral oncology agents. *Clin J Oncol Nur* 19(3 Suppl):31–35
60. Manning M, Bettencourt A (2011) Depression and medication adherence among breast cancer survivors: bridging the gap with the theory of planned behaviour. *Psychol Health* 26(9):1173–1187
61. Latter S, Sibley A, Skinner TC et al (2010) The impact of an intervention for nurse prescribers on consultations to promote patient medicine-taking in diabetes: a mixed methods study. *Int J Nurs Stud* 47(9):1126–1138
62. World Health Organization (2003) Adherence to long-term therapies: evidence for action. Geneva, Switzerland
63. Gearing RE, El-Bassel N, Ghesquiere A, Baldwin S, Gillies J, Ngeow E (2011) Major ingredients of fidelity: a review and scientific guide to improving quality of intervention research implementation. *Clin Psychol Rev* 31(1):79–88
64. Bellg AJ, Borrelli B, Resnick B et al (2004) Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. *Health Psychol* 23(5):443–451
65. Santacroce SJ, Maccarelli LM, Grey M (2004) Intervention fidelity. *Nurs Res* 53(1):63–66
66. Kearney MH, Simonelli MC (2006) Intervention fidelity: lessons learned from an unsuccessful pilot study. *Appl Nurs Res* 19(3):163–166
67. Airhihenbuwa CO, Ford CL, Iwelunmor JI (2014) Why culture matters in health interventions: lessons from HIV/AIDS stigma and NCDs. *Health Educ Behav* 41(1):78–84
68. Fisher TL, Burnet DL, Huang ES, Chin MH, Cagney KA (2007) Cultural leverage: interventions using culture to narrow racial disparities in health care. *Med Care Res Rev* 64(5 Suppl):243S–282S
69. Hamilton JB, Agarwal M, Song L, Moore MAD, Best N (2011) Are psychosocial interventions targeting older African American cancer survivors culturally appropriate? A review of the literature. *Cancer Nurs* 35(2):E12–E23
70. Jeffe D, Perez M, Yan Y et al (2015) African American breast cancer survivor stories: trial usage of a cancer-communication video program. *Ann Behav Med* 49(Suppl 1):s5
71. Baezconde-Garbanati LA, Chatterjee JS, Frank LB et al (2014) Tamale Lesson: a case study of a narrative health communication intervention. *J Commun Healthc* 7(2):82–92
72. Champion VL, Springston JK, Zollinger TW et al (2006) Comparison of three interventions to increase mammography screening in low income African American women. *Cancer Detect Prev* 30(6):535–544
73. Heiney SP, Adams SA, Khang L (2014) Agreement between patient self-report and an objective measure of treatment among African American women with breast cancer. *J Oncol Navig Surviv* 5(3):21–27
74. Felder TM, Palmer NR, Lal LS, Mullen PD (2011) What is the evidence for pharmaceutical patient assistance programs? A systematic review. *J Health Care Poor Underserved* 22(1):24–49
75. Amaro H, Morrill AC, Dai J, Cabral H, Raj A (2005) Heterosexual behavioral maintenance and change following HIV counseling and testing. *Health Psychol* 10(2):287–300
76. Amico KR, Barta W, Konkle-Parker DJ et al (2009) The information-motivation-behavioral skills model of ART adherence in a Deep South HIV + clinic sample. *AIDS Behav* 13:66–75
77. Starace F, Massa A, Amico KR, Fisher JD (2006) Adherence to antiretroviral therapy: an empirical test of the information-motivation-behavioral skills model. *Health Psychol* 25(2):153–162